r Autologous cardiac progenitor cell (CPC) therapy is a promising approach for treatment of heart failure (HF). There is an unmet need to identify inherent deficits in aged/diseased human CPCs (hCPCs) derived from HF patients in the attempts to augment their regenerative capacity prior to use in the clinical setting.
Introduction
Heart failure (HF) remains a major cause of death worldwide due to current inefficient therapies. Autologous stem cell therapy holds promise for mediating cardiac repair following injury. c-Kit + cardiac-derived progenitor cells (CPCs) have proven efficacy in improving cardiac function following myocardial infarction in small animal models (Beltrami et al. 2003; Ellison et al. 2013) . The Stem Cell Infusion in Patients with Ischemic Cardiomyopathy (SCIPIO) clinical trial using autologous c-Kit + CPCs (hCPCs) validated the feasibility and safety of this approach (Bolli et al. 2011; Chugh et al. 2012) . However, hCPCs from multiple patients exhibit varying growth rates and senescence features, which possibly accounts for the modest and inconsistent therapeutic outcomes observed in the clinical setting. Hence, there is an unmet need to identify the molecular components implicated in rejuvenating hCPCs and enhancing their regenerative capacity towards an improved therapeutic outcome in HF patients.
Stem cell capacity to detect stress-induced extracellular signals is critical for initiating regenerative responses following injury. In this regard, it is necessary to understand the molecular mechanism regulating purinergic receptor signalling mediated by extracellular nucleotides released during injury/stress. This study focuses on extracellular UDP-conjugated sugars and their membrane receptor P2Y 14 (P2Y 14 R).
UDP-conjugated sugars such as UDP-glucose (UDPGlu) are synthesized in the cytosol then translocated into the lumen of endoplasmic reticulum and Golgi apparatus where they regulate carbohydrate synthesis and mediate glycosylation reactions by serving as donor substrates (Abeijon & Hirschberg, 1992; Berninsone & Hirschberg, 1998) . In addition to their established intracellular roles, UDP-sugars are secreted from the cell where they act as extracellular signalling molecules (Kreda et al. 2007 (Kreda et al. , 2008 . UDP-Glu is usually released at lower rates than other nucleotides such as ATP, but hydrolysed at a much slower rate, which results in higher steady-state levels of UDP-Glu in the extracellular compartment (Lazarowski et al. 2003) . As an extracellular signalling molecule, UDP-Glu binds to and activates the ubiquitously expressed Gαi protein-coupled P2Y 14 R, also known as GPR105. Since its initial characterization over 15 years ago (Chambers et al. 2000) , an increasing body of literature has described diverse physiological responses downstream of P2Y 14 R in a variety of tissues. P2Y 14 R regulates cell proliferation (Scrivens & Dickenson, 2005) , migration (Jokela et al. 2014) and maturation (Skelton et al. 2003) . Moreover, UDP-Glu triggers chemotaxis of macrophages (Xu et al. 2012) , neutrophils (Sesma et al. 2012; Barrett et al. 2013 ) and a subset of haematopoietic stem cells (HSCs) (Kook et al. 2013 ) in a P2Y 14 R-dependent manner. Furthermore, HSCs isolated from P2Y 14 R knockout mice show impaired capability of restoring hematopoiesis in irradiated mice compared to HSCs derived from wild-type mice, indicating an indispensible role of P2Y 14 R in promoting regenerative responses after injury (Cho et al. 2014) .
Impaired regenerative capacity of P2Y 14 R-deficient HSCs was coupled with increased susceptibility to senescence in response to various stress stimuli, including chemotherapy, irradiation, environmental stresses and ageing (Cho et al. 2014) . Induction of cellular senescence is regulated by an intricate signalling network that involves activation of p16
INK4a , p53 and p21 signalling pathways along with generation of high levels of reactive oxygen species (ROS) (Ziegler et al. 2015) . Interestingly, P2Y 14 R deletion in HSCs resulted in upregulation of molecular markers of senescence, including p16 INK4a and ROS (Cho et al. 2014) . These results highlight a potential role of P2Y 14 R in antagonizing stem cell senescence. Here, we hypothesize that P2Y 14 R mediates similar pro-regenerative and anti-senescence responses in hCPCs derived from cardiac biopsies of HF patients.
The present study was designed to assess correlations between P2Y 14 R expression, hCPC phenotypic characteristics and clinical parameters of patients from which hCPCs were derived. These results were extended by testing the effect of P2Y 14 R activation or overexpression upon improving hCPC functional responses and reversing senescence-associated phenotypes. Findings from this study are discussed in the context of augmenting hCPC phenotypic properties ex vivo via pharmacological or genetic engineering approaches.
Methods

Ethical approval
Human tissue specimens used in this proposal are derived from heart failure patients undergoing left ventricular assist device (LVAD) implantation surgeries. These tissue samples are routine discards from the surgical procedure. There is no additional risk to the patient as the samples are thrown away if not used and would need to be harvested as part of the procedure. Details relating to patient involvement and consent are being conducted and approved by the Sharp Hospital where the samples are acquired (IRB #120686). The samples provided for use in this proposal are de-identified and of no potential therapeutic or diagnostic value to the patients. Therefore, these samples are considered non-human subjects research working with cell lines procured as part of the Sussman lab environment and available for use in relevant studies involving the biology of human cardiac stem cells.
Human cardiac progenitor cell isolation and culture
Human CPCs (hCPCs) ( Table 1) were isolated from cardiac biopsies of heart failure patients undergoing LVAD implantation surgeries as previously described (Mohsin et al. 2013) . Briefly, tissue was minced and digested in collagenase (150 U mg mL −1 ) (Worthington Biochemical Corporation; Lakewood, NJ, USA) at 37°C for 2 h. Digested tissue was sorted with c-Kit-labelled beads (Miltenyi Biotec; San Diego, CA, USA) according to the manufacturer's protocol. Pelleted c-Kit + cells were cultured and expanded in hCPC growth media composed of Ham's F12 (Fisher Scientific; Hampton, NH, USA), 10% embryonic stem cell screened fetal bovine serum (ES FBS), 5 mU mL −1 human erythropoietin (Sigma Aldrich; St. Louis, MO, USA), 10 ng mL −1 basic fibroblast growth factor (Peprotech; Rocky Hill, NJ, USA) and 1% penicillin/streptomycin/glutamine (PSG), and incubated in a humidified atmosphere of 5% CO 2 and 95% air at 37°C.
Real-time reverse transcriptase polymerase chain reaction
Total RNA isolation from cultured hCPCs and cDNA synthesis were performed using Quick-RNA MiniPrep (Zymo Research; Irvine, CA, USA) and iScript cDNA Synthesis Kit (Bio-Rad; Hercules, CA, USA), respectively, according to manufacturers' protocols. iQ SYBER Green (Bio-Rad) was used to prepare samples for quantitative real-time polymerase chain reaction (qRT-PCR). Primer sequences are listed in Table 2 .
Cell proliferation assay hCPC proliferation was assessed using CyQuant fluorescent nucleic acid-based dye (Life Technologies; Carlsbad, CA, USA) according to manufacturer's protocol. CyQuant dye labels live cells where the fluorescence intensity directly correlates with cell number. In agonist stimulation experiments, hCPCs were seeded in serumstarved medium (Ham's F12 medium supplemented with 2.5% ES FBS) in a 96-well plate (500 cells well −1 ) and then treated with CyQuant reagent for 1 h; fluorescence intensity was measured using a plate reader to record baseline (day 0) readings. Cells were treated with or without UDP-glucose (100 μM) (Sigma Aldrich) and after 24 h CyQuant dye was added and the day 1 reading recorded. In overexpression experiments, hCPC proliferation was assessed 5 days after culture in growth medium using haemocytometer counting.
Cell migration assay
hCPC single-cell suspensions were cultured in a 96-well plate coated with growth factor reduced (GFR) Matrigel (BD Biosciences; San Jose, CA, USA) (1600 cells well −1 ) in serum-free Ham's F12 medium and incubated at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. After 2 h, the cell culture plate was mounted on a DMI6000 Leica time-lapse live imaging microscope equipped with a digital camera, an automatic shutter, a motorized x-y stage and an OKO stage top incubator to maintain 37°C, 5% CO 2 and 95% air throughout the duration of the experiment. Bright field images of the selected fields were collected with a 5× objective every 30 min for 2 h. Cell migration was assessed by measuring the distance that cells travelled from origin using Leica LAX software. Cell velocity was calculated by dividing distance travelled from origin over time.
Cell death assay
hCPCs were cultured in a 6-well plate (30,000 cells well −1 ) in growth medium overnight. The next day, cells were subjected to either serum-free medium for 48 h or H 2 O 2 (300 μM) (Sigma Aldrich) in serum-free medium for 24 h. After the indicated times, cells were resuspended in 700 μl Annexin V binding buffer (BD Pharmingen; Franklin Lakes, NJ, USA). Cells were stained with Annexin V (BD Pharmingen) for 10 min to detect apoptotic cells. Cells were pelleted and resuspended in 300 μl Annexin V binding buffer to minimize non-specific binding. Then cells were stained with propidium iodide (PI) (Invitrogen; Carlsbad, CA, USA) for 1 min to detect necrotic cells. The percentage of apoptotic/necrotic cells was measured using flow cytometric analysis.
Morphometric analysis
Bright field images of cultured hCPCs were obtained using a Leica DMIL inverted tissue culture phase contrast microscope (10× magnification). Cell morphology was assessed by measuring Length-to-Width ratio (L/W = Feret/min Feret), Area and Roundness using ImageJ software.
MitoSOX staining
To detect levels of mitochondrial ROS, hCPCs were labelled with MitoSOX Red (ThermoFisher; Waltham, MA, USA) according to manufacturer's protocol. Briefly, hCPCs were cultured in a six-well plate (30 cells well −1 ) overnight then loaded with 5 μM MitoSOX reagent and incubated at 37°C, 5% CO 2 and 95% air for 10 min. Cells were washed with PBS, detached using cell stripper/TrypLE (1:1), pelleted and resuspended in fresh growth medium. MitoSOX mean fluorescence intensity (MFI) was assessed using flow cytometry.
Protein isolation, SDS-PAGE and immunoblot analysis
hCPCs cultured in a six-well plate were collected in 50 μL of sample buffer, sonicated and boiled. Protein lysates were run on 4-12% NuPage Novex Bis Tris gel (Invitrogen), transferred onto a polyvinylidene fluoride (PVDF) membrane and blocked in Odyssey blocking buffer for 1 h at room temperature. Blocked membranes were incubated with primary antibodies at 4°C overnight, then washed several times in Tris-buffered saline Tween-20 solution (TBST) and incubated with secondary antibodies (1:5000) for 1 h at room temperature. Fluorescence signal was detected using an Odyssey imaging scanner and quantified using ImageJ software (Amersham Biosciences; Little Chalfont, UK). Antibodies used are listed in Table 3 . 
Lentiviral-mediated transduction of human cardiac progenitor cells
hCPCs were seeded in a six-well plate (30,000 cells well −1 ) overnight then transduced with lentiviral particles encoding monomeric green fluorescent protein (multiplicity of infection (MOI) 2; hCPC-mGFP) or P2Y 14 R fused to mGFP (MOI 0.2; hCPC-Y14) (lentiviral plasmids were purchased from Origene (Rockville, MD, USA), P2Y 14 R-mGFP plasmid SKU: RC224391L2). P2Y 14 R overexpression was performed in three representative hCPC lines: H10-001, H12-053 and H13-065.
Statistical analysis
Quantified data are presented as the means ± SEM of data from at least three experiments. Statistical analysis was performed using a two-tailed Student's t test or Pearson correlation analysis, as indicated, where P < 0.05 represents a significant difference (GraphPad Prism software version 5.0; La Jolla, CA, USA).
Results
Differential expression of P2Y 14 R in hCPCs isolated from multiple heart failure patients
Correlations between P2Y 14 R expression in hCPCs and clinical parameters of patients were assessed. P2Y 14 R expression in hCPCs directly correlated with ejection fraction (EF) of patients from which hCPCs were derived where lower EF corresponded to lower P2Y 14 R expression, i.e. higher normalized cycle number (R 2 = −0.8833, P = 0.0036) (Fig. 1A) . Diabetes, a common comorbidity in HF patients, reduces number and functional capacity of CPC population (Leonardini & Avogaro, 2013) . Interestingly, P2Y 14 R expression was significantly downregulated in hCPCs isolated from cardiac biopsies of diabetic HF patients compared to non-diabetic control group (normalized cycle number in diabetic group 25.94 ± 1.26 and non-diabetic group 21.81 ± 0.73, P = 0.0291) (Fig. 1B) . The impact of P2Y 14 R activation with its agonist UDP-glucose (UDP-Glu) was assessed in multiple hCPC lines. hCPCs with lower P2Y 14 R expression derived from diabetic HF patients with lower EF did not show increased proliferation in response to UDP-Glu stimulation (H10-001: 1.086 ± 0.065 fold change, P = 0.2230; H12-053: 0.997 ± 0.068 fold change, P = 0.2173) (Fig. 1C) . In contrast, proliferation of hCPC lines with higher P2Y 14 R expression isolated from non-diabetic HF patients with relatively higher EF was enhanced following UDP-Glu treatment (Fig. 1C ) (H13-061: 1.498 ± 0.133 fold change, P = 0.0333; H13-070: 1.803 ± 0.057 fold change, P = 0.0008). Collectively, these findings show significant correlations between clinical parameters of HF patients and expression/functional response of P2Y 14 R in hCPCs.
Activation of ERK1/2 and AKT signalling by the P2Y 14 R agonist UDP-glucose
Mechanistically, hCPC stimulation with UDP-Glu prompted activation of canonical proliferation signalling pathways ERK1/2 and AKT as indicated by increased phosphorylation at ERK1/2 Thr202/Tyr204 (5 min: 1.70 ± 0.15 fold change; 10 min: 1.61 ± 0.14 fold change; 15 min: 1.22 ± 0.23 fold change, P = 0.0051) ( Fig. 2A-C) and AKT Ser473 (5 min: 1.40 ± 0.15 fold change; 10 min: 1.35 ± 0.11 fold change, P = 0.0017) (Fig. 2D-F) .
Improving hCPC proliferation and migration by P2Y 14 R overexpression
To assess whether augmenting P2Y 14 R expression improves hCPC phenotypic properties, cells were transduced with lentiviral particles encoding P2Y 14 R fused to mGFP (hCPC-Y14) or mGFP alone (hCPC-mGFP) as a control. Transduction efficiency was 98.47 ± 0.3828% for hCPC-mGFP and 94.47 ± 4.007% for hCPC-Y14 as J Physiol 595.23 assessed by flow cytometric analysis for percentage of GFP + cells (Fig. 3A and B) . Expression of the P2Y 14 RmGFP fused construct was confirmed by immunoblotting (Fig. 3C) .
P2Y 14 R stimulates cell proliferation and migration in a variety of experimental models (Sesma et al. 2012; Barrett et al. 2013; Kook et al. 2013; Jokela et al. 2014) . Similarly, P2Y 14 R overexpression significantly improved hCPC proliferation (1.441 ± 0.1563 fold change, P = 0.0372) (Fig. 3D ) and enhanced cell migration as shown by increased distance travelled from the origin on GFR Matrigel (1.372 ± 0.03291 fold change, P = 0.0077) (Fig. 3E) . These results confirm the role of P2Y 14 R in stimulating hCPC proliferative and migratory responses.
Enhancing hCPC resistance to cell death by P2Y 14 R overexpression P2Y 14 R expression is essential for HSC resistance to various stress stimuli (Cho et al. 2014) . To test whether P2Y 14 R plays similar roles in hCPCs, hCPC-Y14 and control hCPC-mGFP were subjected to nutrient deprivation by culturing in serum-free medium for 48 h. The percentage of cells undergoing apoptosis or necrosis was assessed using Annexin V or propidium iodide (PI), respectively (Fig. 4A) . hCPC-Y14 showed significantly higher resistance to cell death as indicated by an increase in the percentage of Annexin V − /PI − healthy population (1.12 ± 0.0056 fold change, P = 0.0022) and a decrease in apoptotic cells (0.803 ± 0.0277 fold change, P = 0.0191) 
(t)]). B, P2Y14
mRNA expression is also significantly downregulated in hCPCs isolated from HF patients diagnosed with diabetes mellitus. Cycle numbers were normalized to 18S and data are represented relative to hCPCs from non-diabetic patients. * P < 0.05 indicates significant difference as measured by unpaired Student's t test. C, hCPCs derived from multiple HF patients showed differential response to P2Y 14 R agonist UDP-glucose (UDP-Glu). Each bar represents a hCPC line with corresponding clinical information in the table below. While hCPCs isolated from diabetic HF patients with low EF did not respond to UDP-Glu, hCPCs from non-diabetic patients with relatively higher EF exhibited enhanced proliferation following UDP-Glu treatment for 24 h. Cell proliferation was assessed using CyQuant fluorescent nucleic acid-based dye that labels live cells where the fluorescence intensity directly correlates with the proliferation rate. * P < 0.05 and * * * P < 0.001 indicate significant difference from non-treated control as measured by paired Student's t test.
with no significant effect on percentage of necrotic cells (Fig. 4B) . Additionally, hCPC-Y14 and hCPC-mGFP cell death was assessed following H 2 O 2 -induced oxidative stress (300 μM) in serum-free medium for 24 h (Fig. 4C) . Similarly, hCPC-Y14 demonstrated enhanced survival (1.447 ± 0.0395 fold change, P = 0.0077) and reduced apoptosis (0.76 ± 0.0101 fold change, P = 0.0018) with no significant effect on cell necrosis (Fig. 4D) . These findings suggest a pro-survival role mediated by P2Y 14 R under stress conditions.
Reversing hCPC senescence-associated phenotypes by P2Y 14 R overexpression P2Y 14 R deletion enhances stress-induced senescence in HSCs (Cho et al. 2014) . To demonstrate whether P2Y 14 R mediates anti-senescence responses in hCPCs, the impact of P2Y 14 R overexpression upon cell morphology and expression of senescence markers was assessed. hCPC-Y14 exhibited a 'spindly' morphology characteristic of a more proliferative and less senescent hCPC population (Fig. 5A ). This was indicated by increased cell length/width ratio (from 3.848 ± 0.0884 to 5.325 ± 0.5607 arbitrary units, P = 0.0405) (Fig. 5B) , decreased area (from 5868 ± 465.4 to 4873 ± 280.4 arbitrary units, P = 0.1411) (Fig. 5C ) and roundness (from 0.2967 ± 0.0022 to 0.2534 ± 0.0097 arbitrary units, P = 0.0048) (Fig. 5D) . P2Y 14 R-induced changes in morphology were associated with downregulation of canonical molecular markers of senescence p16
INK4a (0.2917 ± 0.0475 fold change, P = 0.0045) (Fig. 6A and D) , p53 (0.798 ± 0.0245 fold change, P = 0.0144) ( Fig. 6B and E) and p21 (0.5590 ± 0.0842 fold change, P = 0.0012) (Fig. 6C and  F) . Moreover, P2Y 14 R overexpression reduced levels of mitochondrial ROS as shown by diminished MitoSOX mean fluorescence intensity (MFI) in hCPC-Y14 compared to hCPC-mGFP (from 485.5 ± 33.89 to 329.3 ± 11.23 arbitrary units, P = 0.0119) (Fig. 6G) . These findings implicate an anti-senescence role for P2Y 14 R in hCPCs.
Discussion
Human CPCs (hCPCs) isolated from heart failure (HF) patients with genetic predispositions, concomitant underlying chronic diseases such as diabetes, obesity and hypertension, and/or habitual stressors such as alcoholism and smoking exhibit severely compromised regenerative potential. Therefore, there is an unequivocal need to reveal the molecular mechanisms involved in rejuvenating these cells and enhancing their phenotypic characteristics towards a better reparative potential of the damaged myocardium (Mohsin et al. 2012 (Mohsin et al. , 2013 Kulandavelu et al. 2016) . This study introduces P2Y 14 R as an important regulator of hCPC proliferative, migratory and survival responses. Moreover, findings from the present study reveal an anti-senescence role mediated by P2Y 14 R in hCPCs through retaining cellular morphology and B and C, E and F) showing enhanced phosphorylation of ERK1/2 and AKT (indicating activation) in response to UDP-Glu (100 μM) treatment. pERK1/2 Thr202/Tyr204 and pAKT Ser473 were normalized to total ERK1/2 (n = 5) and total AKT levels (n = 6), respectively. Total ERK1/2 (n = 8) and total AKT levels (n = 8) were normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase; loading control). Data are represented relative to 0 min (no UDP-Glu treatment). * P < 0.05 and * * P < 0.01 indicate significant difference from 0 min as measured by one-way ANOVA followed by Dunnett's post hoc test. -Y14; B) . C, a representative immunoblot showing a 38 kDa band corresponding to endogenous P2Y 14 R in hCPCs overexpressing P2Y 14 R and mGFP (hCPC-Y14) and control hCPCs expressing mGFP alone (hCPC-mGFP) in addition to a shifted 65 kDa P2Y 14 R band in hCPC-Y14 validating overexpression of the P2Y 14 R-mGFP fused construct at the protein level. D, proliferation analysis over the course of 5 days demonstrating that hCPC-Y14 cells exhibit enhanced proliferation. Cell proliferation was assessed as described in Fig. 1 . E, migration analysis showing that P2Y 14 R overexpression significantly enhances hCPC migration on GFR Matrigel as indicated by increased distance that cells travelled from origin. Cell migration was monitored for 2 h using live-cell imaging. * P < 0.05 and * * P < 0.01 indicate significant difference from hCPC-mGFP as measured by paired Student's t test. molecular signature that typify a more youthful stem cell population (Fig. 7) .
The regenerative capacity of CPCs progressively declines with age and age-related chronic diseases (Capogrossi, 2004; Dimmeler & Leri, 2008; Cesselli et al. 2011) rendering limited therapeutic potential of stem cells isolated from HF patients (Bolli et al. 2011; Chugh et al. 2012) . Rejuvenation of hCPCs with advanced biological age is crucial for augmenting functional activity and regenerative properties. Findings from this study demonstrate that P2Y 14 R overexpression reverses senescence-associated phenotypes in aged hCPCs derived from HF patients. P2Y 14 R-overexpressing hCPCs exhibit a 'spindly' morphology and reduced levels of p16
INK4a , p53, p21 and mitochondrial ROS characteristic of a less senescent stem cell population. These results are consistent with the anti-senescence roles of P2Y 14 R previously demonstrated in HSCs where P2Y 14 R deletion resulted in enhanced susceptibility to stress-induced senescence and elevated expression levels of the senescence markers p16
INK4a , hypophosphorylated retinoblastoma protein (Rb) and ROS (Cho et al. 2014 ).
Myocardial regeneration mediated by resident or adoptively transferred progenitor cells is severely limited due to poor survival rates in the unfavourable environment of the necrotic tissue (Hofmann et al. 2005; Rota et al. 2007) . Antagonizing senescence in aged hCPCs has proven efficacy in improving survival capability and functional capacity both in vitro and in vivo (Mohsin et al. 2012 (Mohsin et al. , 2013 . Similarly, P2Y 14 R-mediated anti-senescence responses were associated with improved hCPC survival under various stress stimuli including serum deprivation and H 2 O 2 -induced oxidative stress.
Additionally, P2Y 14 R overexpression significantly improved hCPC proliferation by 1.44-fold as assessed by haemocytometer counting after 5 days in culture. These data extend previous findings showing enhancement of hCPC proliferative capacity using different interventional approaches. Engineering cells with Pim1 kinase improves hCPC proliferation by 1.2-to 1.4-fold as assessed by CyQuant assay after 3 days in culture (Mohsin et al. 2013) . A more profound effect on hCPC proliferation was achieved by targeting Pim1 to specific intracellular compartments. Overexpressing nuclear-targeted C and D) showing that hCPC-Y14 exhibit a higher percentage of live cells, lower levels of apoptotic cells and no significant effect on cell necrosis. Cell apoptosis and necrosis were assessed by Annexin V and propidium iodide (PI) staining, respectively, followed by flow cytometric analysis. * P < 0.05 and * * P < 0.01 indicate significant difference from hCPC-mGFP control group as measured by paired Student's t test.
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Pim1 increases hCPC proliferation by 2.21-fold whereas targeting Pim1 to mitochondria enhances proliferative response by 2.78-fold as determined by CyQuant assay after 3 days in culture (Samse et al. 2015) . In addition to genetic engineering, pharmacological approaches have been pursued to enhance hCPC proliferative capacity. ATP preconditioning improves atrial-derived c-Kit + hCPC proliferation by ß2-fold as measured by BrdUrd incorporation (Ferreira-Martins et al. 2009 ). Modulating oxygen levels is an alternative approach that significantly impacts proliferative response in hCPCs. Transferring human endomyocardial biopsy-derived c-Kit + cardiac stem cells from atmospheric oxygen (21%) to physiological oxygen (5%) improved cell proliferation by 1.4-fold by day 3 and 1.5-fold by day 4 in culture as assessed by a TC10 automated cell counter (Bellio et al. 2016) . Collectively, multiple molecular interventions improve CPC growth to varying levels; however, the differences observed could be partially impacted by varying origins and culture procedures of isolated c-Kit + cells, techniques used to measure cell proliferation and/or time points at which cell proliferation was assessed.
In addition to improving hCPC survival and proliferation, P2Y 14 R overexpression enhanced migratory responses on GFR Matrigel, indicating an overall improvement in cellular properties critical for the regeneration process. These findings are in agreement with prior literature showing a central role of P2Y 14 R in mediating proliferation of keratinocytes (Jokela et al. 2014) , migration of neutrophils (Sesma et al. 2012; Barrett et al. 2013) and haematopoietic stem cells (HSCs) (Kook et al. 2013) in addition to maintaining the regenerative capacity of HSCs following injury (Cho et al. 2014) .
Purinergic receptors are activated by extracellular nucleotides released following injury/stress to induce cellular responses required for the repair process (Burnstock, 1997; Erb et al. 2006) . Lack of purinergic receptor expression could lead to impaired regenerative responses to injury. Striking correlations existed between P2Y 14 R expression in hCPCs and clinical parameters of HF patients from which hCPCs were derived. hCPCs from patients with relatively lower ejection fraction (EF) exhibited lower P2Y 14 R expression. In addition, P2Y 14 R was significantly downregulated in hCPCs isolated from HF patients diagnosed with diabetes, previously linked to a functionally defective CPC population due to enhanced inflammation, hyperglycaemia, hyperlipidaemia and oxidative stress in diabetic patients Cell morphology was analysed using ImageJ software. * P < 0.05 and * * P < 0.01 indicate significant difference from hCPC-mGFP control as assessed by unpaired Student's t test. (Leonardini & Avogaro, 2013) . Altogether, these findings point to P2Y 14 R as a biomarker of hCPC functional capacity that can be used to enrich for a more youthful subset of hCPC population.
Future studies will be dedicated to assessing the inclusion of additional steps to further augment the functional capacity of hCPCs engineered with P2Y 14 R (hCPC-Y14). For instance, hCPC-Y14 can be subjected to hypoxia preconditioning since unpublished data from our group and recent reports show that modulating O 2 concentration significantly impacts the regenerative potential of CPCs (Bellio et al. 2016) . It is also likely that purinergic receptors act in a cooperative manner. Studies to evaluate other potential purinergic receptor candidates to improve the regenerative capacity of hCPCs are currently underway. Co-expression of more than one purinergic receptor could induce synergistic effects towards a better therapeutic outcome. In vitro results will be extended to an in vivo model of myocardial infarction to test the reparative potential of modified hCPCs for injured myocardium.
Overall, identifying intrinsic deficits in hCPCs is an unequivocally essential step towards improving therapeutic efficacy. Defective hCPCs derived from HF patients with relatively lower ejection fraction and/or diagnosed with diabetes show reduced P2Y 14 R expression levels and impaired functional responses. P2Y 14 R overexpression significantly augmented hCPC function and antagonized cellular senescence. These findings set the stage to assess P2Y 14 R overexpression as a potential interventional approach to augment the therapeutic outcome of stem cells derived from injured myocardium for treatment of HF through autologous stem cell therapy. 
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Translational perspective
The regenerative capacity of stem cells is largely dependent on their ability to communicate with the extracellular environment and react with the proper responses. In this regard, transmembrane purinergic receptors represent a major detector for extracellular nucleotides released during injury/stress and serve as an intracellular platform harbouring numerous signalling pathways that play critical roles in regulating inflammatory and regenerative responses required for the healing process following injury. Findings from this study demonstrate significant correlations between P2Y 14 purinergic receptor (P2Y 14 R) expression in human cardiac progenitor cells (hCPCs) isolated from cardiac biopsies of heart failure patients and their clinical profiles. P2Y 14 R expression was downregulated in hCPCs derived from heart failure patients with low ejection fraction or diagnosed with diabetes. Augmenting P2Y 14 R expression levels in aged/diseased hCPCs reverses cellular senescence and boosts survival, proliferative and migratory responses. Restoring the youthful phenotype of hCPCs enhances engraftment and regenerative capacity. Therefore, engineering hCPCs with P2Y 14 R could improve reparative potential upon adoptive transfer into infarcted myocardium with the long-term goal of translational application in autologous stem cell therapy. P2Y 14 R-engineered hCPCs could display enhanced capability to detect extracellular UDP-sugars released during injury/stress and improve therapeutic efficacy of hCPCs. Indeed, this concept is not restricted to hCPCs and can be extended in other types of stem cells used for autologous or allogeneic cell therapy for treatment of HF.
